-
Chem: Soochow University Liu Zhuang/Cheng Liang team prepared nano-scale CaH₂ to help hydrogen/immune synergistic anti-cancer therapy Cell Press paper express
Time of Update: 2022-02-21
Cheng Liang of Soochow University prepared calcium hydride nanoparticles (nano-CaH2) by liquid phase exfoliation method to realize hydrogen-immune synergistic therapy, which can effectively inhibit tumor growth .
-
Surprise to win!
Time of Update: 2022-02-21
Recommended reading: Non-viral "allogeneic" CAR-T therapy is about to enter the clinic, targeting multiple solid tumorsYimai Meng broke the news In the same month, Lyell announced that its CAR-T cell therapy LYL797 has been approved by the FDA IND.
-
2022 ASCO GI | DESTINY-CRC01 study: DS-8201 is expected to treat HER2-positive metastatic colorectal cancer
Time of Update: 2022-02-21
DESTINY-CRC01, a phase II, multicenter, open-label study in patients with HER2-positive metastatic colorectal cancer, reported good efficacy and safety of the antibody-conjugated drug Trastuzumab deruxtecan (T-DXd; DS-8201) Controllable, the following is the research details .
-
$1.5 billion worth!
Time of Update: 2022-02-21
Recommended reading: The CD3/CD20 double antibody purchased by Zai Lab has been approved for clinical use, and the double/multi-specific antibody drug has become a research and development trendYimai Meng broke the news of Roche CD3/CD20 Double antibodies are planned to be included in breakthrough therapy varietiesYimai Meng revealed that the development of TEB in solid tumors is slightly slower, mainly because of the difficulty in target selection and the high toxicity in normal tissues .
-
PD-L1 expression changes from yin to yang after chemoradiotherapy, bringing opportunities for immunotherapy
Time of Update: 2022-02-21
If the PD-L1 expression in the patient's tumor tissue samples is relatively high, it is possible that the effect of immune checkpoint inhibitor therapy will be better, but this conclusion is still controversial .
-
BEST features of third-generation EGFR-TKIs
Time of Update: 2022-02-21
Professor Han Baohui: In the 16 years since the first EGFR-TKI drug was approved in China for the treatment of advanced NSCLC in 2005, the first-generation, second-generation and third-generation EGFR-targeted targeted therapy drugs have compared Platinum chemotherapy significantly improves progression-free survival, and turning advanced lung cancer into a chronic disease has become a reality for some patients .
-
"Spot-type" CAR-NK therapy is expected to conquer the king of cancer, and clinical trials will begin this year
Time of Update: 2022-02-21
Recently, City of Hope National Medical Center, the world's top cancer research and treatment institution, and CytoImmune Therapeutics, a cell therapy innovation company, jointly published a paper entitled: Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell in Gastroenterology, the top journal of gastroenterology.
-
Anti-angiogenesis + immunotherapy succeeded again, new standard of treatment for advanced endometrial cancer NEJM
Time of Update: 2022-02-21
The trial compared the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy in patients with advanced endometrial cancer whose tumors had progressed after at least one platinum-based chemotherapy .
-
How often should non-smoking young women be screened for lung cancer?
Time of Update: 2022-02-21
The results show that from the perspective of epidemiological characteristics, with the introduction of LDCT screening, the incidence of lung cancer in Taiwanese women increased significantly from 2004 to 2018, but the mortality rate remained stable .
-
2022 ASCO GI AK104 combined with chemotherapy may become a new first-line treatment option for patients with advanced G/GEJ adenocarcinoma
Time of Update: 2022-02-21
We conducted this phase Ib/II study to evaluate the efficacy of AK104 (a PD-1/CTLA-4 bispecific antibody) in combination with XELOX (capecitabine and oxaliplatin) or modified XELOX (mXELOX) in Efficacy and safety in first-line treatment of G/GEJ cancer .
-
AGA Journal: Incorporating IL-15, "off-the-shelf" CAR-NK therapy significantly inhibits pancreatic cancer growth
Time of Update: 2022-02-21
January 22, 2022 / eMedClub News/--Recently, CytoImmune announced that its “off-the-shelf” CAR-NK therapy targeting prostate stem cell antigen (PSCA), developed in collaboration with City of Hope, can significantly inhibit Pancreatic cancer, the research results were published in Gastroenterology, an international authoritative journal in the field of gastroenterology .
-
2022 ASCO GI ｜ Multiple research results released, bringing new options for the treatment of colorectal cancer patients
Time of Update: 2022-02-21
GERCOR NIPICOL Phase II Study: Effect of Nivolumab in Combination with Ipilimumab or Background Immune Checkpoint Inhibitor (ICI) for MSI-H/Mismatch Repair Deficient ( The optimal duration of treatment for patients with dMMR) mCRC remains controversial .
-
"Cell" sub-issue: Cancer cells "play for their lives" drug resistance!
Time of Update: 2022-02-21
Figure 1A Schematic diagram of competition experiment First, under standard culture conditions, Sheltzer induced transient CIN using Mps1 inhibitor, which made cancer cells (human melanoma cell line A375) aneuploid, and observed that CIN was harmful to cancer cells; However, in the presence of a certain concentration of the therapeutic drug (vemurafenib), it was observed that CIN accelerated the development of tumor resistance (Fig.
-
Cancer Res Liu Suling/Zhang Lixing/Shao Zhimin/Zhang Xiaoyong of Fudan University Reveal the Important Mechanism of ALDH1A1 Enzyme Activity Promotes Breast Tumor Growth
Time of Update: 2022-02-21
Mechanism of ALDH1A1 enzymatic activity in tumor-initiating cells suppressing immune processes (image courtesy of Cancer Research) In conclusion, this study elucidates the functional and molecular mechanism of ALDH1A1 regulating the interaction of BTICs and MDSCs to promote breast cancer development, which may provide evidence for malignant breast cancer.
-
Talk about progress, talk about practice, look at the future progress of lung cancer MET targets in China, cloud summit held
Time of Update: 2022-02-21
At the meeting, Professor Lu Shun reviewed the research progress of MET-targeted therapy, and looked forward to the development and exploration direction of future clinical diagnosis and treatment .
-
Nature reveals non-genetic determinants of malignant clone fitness at single-cell resolution
Time of Update: 2022-02-21
Dawson from the Peter McCarran Cancer Center in Australia published an article titled Non-genetic determinants of malignant clonal fitness at single-cell resolution online in Nature, using single-cell analysis and lineage tracing (SPLINTR) Tracking of isogenic clones in three clinically relevant mouse models of acute myeloid leukemia revealed that malignant clonal dominance is a cell-inherent heritable property that can be induced by inhibiting antigen presentation and increasing the secretory leukocyte peptidase inhibitor gene ( Slpi) expression to promote .
-
JAMA sub-issue: Whether metformin can "assist" lung cancer treatment, the key may be this indicator!
Time of Update: 2022-02-20
The trial included patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) and randomly assigned to receive EGFR-TKIs alone or the combination of EGFR-TKIs and metformin (500 mg twice daily) .
-
Front Oncol: Real-world data to explore treatment strategies and prognosis in patients with EGFR exon 18-mutated NSCLC
Time of Update: 2022-02-20
713483Xu H, Yang G, Li W, LiJ, Hao X, Xing P, Yang Y and Wang Y (2021) EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes .
-
Prof. Wang Ziping: Baizean® advanced NSCLC first-line indications/medical insurance coverage, second-line/third-line new indications are approved, fully accessible, benefiting all lines!
Time of Update: 2022-02-20
At the same time, based on the excellent efficacy data of the RATIONALE 303 study, a new indication of tislelizumab for the treatment of second- or third-line locally advanced or metastatic NSCLC patients with disease progression after platinum-based chemotherapy was recently approved by the national Approved by the National Medical Products Administration (NMPA) .
-
Express one-step transformation of 4 types of cells, delivery of 5 types of mRNA, innovative solid tumor cell therapy into the clinic
Time of Update: 2022-02-20
▎WuXi AppTec Content Team Editor On January 24, 2022, SQZ Biotechnologies announced that the US FDA has approved its IND application for a Phase 1/2 clinical trial of its mRNA-based cell therapy SQZ-eAPC-HPV .
